Dublin, Oct. 26, 2021 (GLOBE NEWSWIRE) -- The "Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering.
This report examines the current and forecasted market potential of radiopharmaceuticals and therapeutics. It offers a detailed analysis of the technological advancement, competitive environment, market background, drivers and restraints, and market growth trends.
The research report also includes market projections to 2026. The scope of this report is broad and covers type, production method, technology and applications of radiopharmaceuticals and therapeutics. By type, the market has been segmented into radiotherapy and radiopharmaceuticals. Revenue forecasts from 2021 to 2026 are provided for each segment and regional market, with estimated values derived from manufacturers' total revenues.
The global radiopharmaceuticals and therapeutics market should reach $28.5 billion by 2026 from $18.2 billion in 2021 at a compound annual growth rate (CAGR) of 9.4% for the forecast period of 2021 to 2026.
The North American radiopharmaceuticals and therapeutics market is expected to grow from $7.0 billion in 2021 to $11.1 billion in 2026 at a CAGR of 9.5% for the forecast period of 2021 to 2026.
The Asia-Pacific radiopharmaceuticals and therapeutics market is expected to grow from $4.5 billion in 2021 to $7.2 billion in 2026 at a CAGR of 10.0% for the forecast period of 2021 to 2026.
The report additionally includes a discussion of the major market players in radiopharmaceuticals and therapeutics. Further, it explains the major drivers and regional dynamics of the global radiopharmaceutical and therapeutics market and current trends within the industry.
By geography, the radiopharmaceutical and therapeutics market has been segmented into Europe, North America, Asia-Pacific (APAC) and the Rest of the World (RoW).
The detailed analyses of major countries such as the U.S., Germany, Canada, the U.K., Spain, France, Japan, India and China are covered in regional segments. For market estimates, data is provided for 2020 as the base year, 2021 and forecast through year-end 2026. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
52 data tables and 72 additional tables
An overview of the global market for radiotherapy, radiopharmaceuticals, and nuclear medicines
Estimation of the market size and analyses of the global market trends, with data from 2019 to 2020, estimates for 2021, with projection of CAGR through 2026
Analysis of new opportunities, challenges, and technological changes within the industry and highlights of the market potential by type, method, technology, application and region
Assessment of present and future strategies within the radiopharmaceuticals market, including radiopharmaceuticals for both diagnostic and therapeutic purposes
Description of positron emission tomography (PET) and single photon emission computed tomography (SPECT) and discussion of their applications
Evaluation of market opportunities for external beam radiation therapy, internal radiation therapy and systemic radiotherapy
Detailed analysis of the current market trends and forecast, relevant R&D activities, new products launches and product enhancement in the industry and discussion of regulatory elements that are affecting the future marketplace
Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
Company profiles of major players in the market, including Accuray Inc., Bayer Pharma AG, Cardinal Health, General Electric Co., Nordion Inc. and Siemens Healthineers AG
Population and human life expectancy are increasing globally, spurring more chronic conditions and life-threatening diseases. A sedentary lifestyle, obesity and a lack of physical activity have further worsened the situation, leading to the increased importance of medical treatments and interventions.
Despite incredible improvements in the field of medicine in the last few decades, an unmet need remains for the diagnosis, prevention, and treatment of aggressive ailments such as cardiovascular diseases, central nervous system disorders and cancer.
Since the discovery of radioactivity, it has been observed that radiation can play a role in the treatment of several diseases. Radiopharmaceuticals are a type of radioactive drug internally administered and intended to diagnose and treat diseases. Radiopharmaceuticals are now a vital part of the healthcare industry, as they can identify several disease processes much earlier than other diagnostic tests.
Applications of radiopharmaceuticals are rising significantly in the fields of neurology, oncology, cardiology and other medical specialties, such as gastroenterology, endocrinology and nephrology, for therapeutic and diagnostic purposes. Radiopharmaceuticals have also become a necessary part of personalized medicine. The market for therapeutic radiopharmaceuticals is anticipated to grow at a steep rate in the coming years due to growing applications and increased demand.
Growing acceptance and utilization of nuclear medicine scans (i.e., PET and SPECT) and better availability of radiopharmaceuticals due to a growing number of cyclotrons have significantly further contributed to growth in the radiopharmaceutical industry.
Innovative technological devices leading to early and accurate diagnoses, increased awareness of radiopharmaceuticals among patients and physicians and new regulatory approvals of radiopharmaceuticals are other major driving forces for the global radiopharmaceutical market. Furthermore, rising incidences of different types of cancers across the globe are considered a significant driver behind the growth of radiopharmaceuticals and therapeutics.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Regulatory Scenario
Chapter 4 Radiopharmaceuticals and Therapeutics: Background
Uses of Radiopharmaceuticals
Evolution and Transition of Radiopharmaceuticals
Evolution and Transition of Radiation Therapy
The Discovery Period: 1890s
Kilovoltage Era: 1900-1940
Megavoltage Era: 1946-1996
Computer-Assisted Era: 1996-Present
Radiotherapy Subsegments by Type
Radiopharmaceuticals Subsegments by Type
Production Method Subsegments
Radiopharmaceuticals and Therapeutics, by Application
Chapter 5 Market Dynamics
Magnetic Resonance-Driven Linear Accelerator
Increasing Aging Population
Increasing Incidence of Life-Threatening Diseases
Increasing Incidence of Cancer
High Incidence of Cancer in Aging Population
Growing Healthcare Spending in Emerging Regions
Advancements in Technology
Growing Focus on Early Diagnosis and Treatment
Increasing Number of Cyclotrons
Increasing Amount of Nuclear Imaging Equipment
High Efficiency of Radiotherapy
Palliative Radiation Therapy
Restraints and Challenges
Limited Global Supply of Medical Isotopes
Lack of Trained Professionals
Limited Effectiveness against Metastatic Cancer
Side Effects of Radiation Therapy
Replacement of Old Equipment
Chapter 6 Impact of COVID-19 Pandemic
Impact of COVID-19 on Radiopharmaceuticals and Therapeutics
Impact on Cancer Research
Public Health Impact of COVID-19 Across the Cancer Continuum
Chapter 7 Market Breakdown by Type
External Beam Radiation Therapy
Internal Radiation Therapy
Chapter 8 Market Breakdown by Production Method
Particle Accelerators (Cyclotrons)
Particle Accelerator Process
Production of Radioisotopes Through Radionuclides
Chapter 9 Market Breakdown by Technology
External Radiotherapy by Technology
Particle Therapy/Proton Beam Therapy
Stereotactic Radiosurgery (SRS) and Fractionated Stereotactic Radiation Therapy
Image-Guided Radiation Therapy (IGRT)
Intensity-Modulated Radiation Therapy (IMRT)
Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Volumetric Modulated Arc Therapy (VMAT)
Internal Radiotherapy by Technology
Pulsed-Dose-Rate (PDR) Brachytherapy
High-Dose-Rate (HDR) Brachytherapy
Systemic Radiotherapy by Technology
Comparison between Alpha and Beta Emitters
Chapter 10 Market Breakdown by Application
External Beam Radiation Therapy
Treatment Planning for External Beam Radiation
Dosing and Treatment with External Beam Radiation
Electron-Emitting High-Energy Linear Accelerators (LINACs)
Internal Radiation Therapy
Applications of Internal Beam Radiation Therapy
Systemic Radiation Therapy
Applications of Systemic Radiation Therapy
Chapter 11 Market Breakdown by Region
Chapter 12 Patent Analysis
U.S. Patent Analysis
European Patent Analysis
Japanese Patent Analysis
Chapter 13 Competitive Landscape
Global Company Share Analysis
Mergers and Acquisitions
Agreements, Collaborations, Product Launches and Partnerships
Chapter 14 Company Profiles
Advanced Accelerator Applications Sa (Novartis)
Alliance Medical Group
Bayer Pharma Ag
Becton, Dickinson And Co. (Bd)
Bracco Diagnostic Inc.
Coqui Radiopharmaceuticals Corp.
Eckert & Ziegler Bebig
Fujifilm Holdings Corp.
General Electric Co.
Iso-Tex Diagnostics Inc.
Jubilant Draximage Inc.
Lantheus Medical Imaging Inc.
National Centre For Nuclear Research Polatom
National Institute For Radioelements (Ire)
Ntp Radioisotopes Soc Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/sd0ptu
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900